Engineered immunosuppressive dendritic cells protect against cardiac remodelling
Article Meta
Article Date: 08 April 2026
Article URL: https://www.nature.com/articles/s41586-026-10346-5
Article Title: Engineered immunosuppressive dendritic cells protect against cardiac remodelling
Article Image: https://www.nature.com/articles/s41586-026-10346-5/figures/1
Summary
This Nature paper describes the design and testing of FAP-targeted immunosuppressive dendritic cells (iCDCs) engineered to deliver CTLA4-Ig, PD-L1 and IL-10. The constructs combine a fibroblast activation protein (FAP)-specific scFv with immunomodulatory payloads to target activated cardiac fibroblasts after myocardial injury.
In vitro, iCDCs show reduced expression of co-stimulatory molecules and increased inhibitory markers and cytokine secretion, suppressing T cell activation. In multiple in vivo murine models (ischaemia/reperfusion, myocardial infarction and transverse aortic constriction) iCDC therapy reduced inflammation and fibrosis, improved cardiac function and survival, and promoted angiogenesis. Single-cell and spatial transcriptomics reveal broad remodelling of immune, fibroblast and endothelial compartments toward reduced pro-inflammatory and pro-fibrotic programmes.
Safety and translational potential were supported by non-human primate experiments showing improved cardiac volumes and no overt systemic toxicity across haematological, biochemical and histopathological assessments. The authors provide sequencing data and code for reproducibility.
Key Points
- Engineered dendritic cells (iCDCs) target FAP-expressing fibroblasts and deliver CTLA4-Ig, PD-L1 and IL-10 to create a local immunosuppressive niche.
- iCDCs suppress T cell activation in vitro, shifting T cell phenotypes toward regulatory and less inflammatory states.
- In mouse models of MI, I/R and pressure overload, iCDC treatment reduced fibrosis, improved ejection fraction and fractional shortening, and increased survival.
- Single-cell RNA-seq and spatial analyses show iCDCs reprogramme cardiac immune cells, fibroblasts and endothelial cells, inhibiting pro-fibrotic and inflammatory pathways and enhancing repair-associated programmes.
- Non-human primate data indicate improved cardiac volumes after MI and no major systemic toxicity across blood tests, cytokines, organ histology and brain MRI at 3 months.
- Data and code availability: sequencing data deposited (GSA PRJCA041520) and code on GitHub (https://github.com/averycheng-Hulab/iCDC), supporting reproducibility.
Context and relevance
Heart failure and pathological cardiac remodelling remain major global health burdens, and immune-driven fibrosis is increasingly recognised as a key therapeutic target. This work intersects immunotherapy and regenerative cardiology by repurposing engineered antigen-targeted dendritic cells to locally suppress harmful immune responses and fibroblast activation.
The approach is notable because it targets activated fibroblasts (FAP+) to focus immunosuppression where it is needed, potentially avoiding widespread systemic immune suppression. The single-cell and spatial transcriptomic profiling strengthens mechanistic insight and helps identify cellular pathways affected by treatment. The inclusion of non-human primate data increases translational relevance compared with murine-only studies.
Why should I read this?
Quick version: if you care about stopping the nasty fibrosis that follows heart attacks without wrecking the whole immune system, this paper is worth five minutes. It shows a clever cell-therapy trick — dendritic cells engineered to carry immune brakes and home to activated fibroblasts — that tames local inflammation, reduces scarring and improves heart function in mice and primates. The authors back it with single-cell data, safety checks and shared code/data, so it’s actually useful beyond the headline.
Author style
Punchy: this is a high-impact translational advance that combines targeted immunomodulation with rigorous multi-omic profiling and NHP validation. If you follow cardiac repair, immunotherapy or cell therapy, the methods and datasets here are immediately relevant and worth digging into.